Concepedia

Julio Rosenstock

JR

Statistics

Publications

279

Citations

54.2K

H-Index

112

Active since

1985

Affiliations

Dallas Diabetes Research Center(Current)

The University of Texas Southwestern Medical Center

Novo Nordisk (Denmark)

Boehringer Ingelheim (Germany)

Velocity Clinical Research (United States)

Julio Rosenstock is an author at Dallas Diabetes Research Center specializing in clinical pharmacology, diabetes mellitus, and medicine.

ORCID

Publications per year

1985–2025

279

Publications

279

Once-Weekly Semaglutide in Adults with Overweight or Obesity

John Wilding, Rachel L. Batterham, Salvatore Calanna et al. · New England Journal of Medicine · 2021 · 4.5K citations · Full text

, , +11

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

, , +14

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Juan P. Frías, Melanie J. Davies, Julio Rosenstock et al. · New England Journal of Medicine · 2021 · 1.9K citations · Full text

, , +16

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

John B. Buse, Julio Rosenstock, Giorgio Sesti et al. · The Lancet · 2009 · 1.5K citations

, , +13

The Treat-to-Target Trial

Matthew C. Riddle, Julio Rosenstock, John Gerich · Diabetes Care · 2003 · 1.5K citations · Full text

, , +17

1–5 of 279